Vedolizumab (Entyvio) treatment was linked with a lower risk of some infections compared with tumor necrosis factor (TNF) antagonists in patients with ulcerative colitis (UC), researchers reported.
An observational study of health insurance claims found a 46% lower risk of serious infections requiring hospitalization in UC patients given the integrin 4β7-targeting antibody, according to Siddharth Singh, MD, of the University of California San Diego, and colleagues.